Abstract: SA-PO0909
Association Between Serum Lipids and Urine Supersaturation Profiles Among Prevalent Kidney Stone Formers
Session Information
- Health Maintenance, Nutrition, and Metabolism
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Health Maintenance, Nutrition, and Metabolism
- 1500 Health Maintenance, Nutrition, and Metabolism
Authors
- Lu, Jason, Brown University, Providence, Rhode Island, United States
- Shringi, Sandipan, Brown University, Providence, Rhode Island, United States
- Bhattarai, Shreeyukta, Brown University, Providence, Rhode Island, United States
- Cadore Guzzo, Eduardo, Albert Einstein College of Medicine, New York, New York, United States
- Raker, Christina A., Brown University, Providence, Rhode Island, United States
- Tang, Jie, Brown University, Providence, Rhode Island, United States
Background
Dyslipidemia is prevalent among kidney stone (KS) formers, but results from prior studies examining its association with KS risk have been inconsistent.
Methods
This was a single-center retrospective study of adult prevalent KS formers who underwent 24-hour urine supersaturation and lipid studies within six months. Associations between serum lipid parameters and urinary KS supersaturation measurements were evaluated using linear regression, with lipid levels modeled both as continuous variables and as categorical variables in quartiles (Q). Models used were M1(unadjusted), M2(adjusted for statin), M3(adjusted for statin, demographics, urine volume and urine sulfate, and M4(adjusted for M3+lipid values mutually adjusted; i.e. for low-density liproproteins (LDL), adjustment was made for high-density liproproteins (HDL) and Triglycerides (TG)).
Results
A total of 193 KS formers were included, median age was 55 years, 40% were males, 75% were Caucasian White, 34% had dyslipidemia, and 33% used statins. As demonstrated in the table, higher LDL levels were associated with increased calcium phosphate (CaP) supersaturation and decreased uric acid (UA) supersaturation across all models. However, no association was found with calcium oxalate supersaturation. Regarding TG and HDL, no association with any of the supersaturation measurements were found after multivariable adjustment.
Conclusion
Higher LDL appears to be associated with a higher CaP but lower UA KS risk. Future large population-based studies are needed to confirm these risk associations.
Association between Serum Lipids and Urine Supersaturation Profiles among Kidney Stone Formers
| Lipid | Urine SS outcome | M1: β (p) | M1: Q4 vs. Q1 β (p) | M2: β (p) | M2: Q4 vs. Q1 β (p) | M3: β (p) | M3: Q4 vs. Q1 β (p) | M4: β (p) | M4: Q4 vs. Q1 β (p) |
| Low-density lipoprotein | Calcium oxalate | -0.17% (0.22) | -8.1% (0.54) | -0.20% (0.18) | -11.0% (0.42) | -0.09% (0.53) | -1.3% (0.93) | -0.11% (0.47) | -2.9% (0.85) |
| Calcium phosphate | 0.43% (0.05) | 70.4% (0.02) | 0.43% (0.06) | 70.0% (0.02) | 0.46% (0.04) | 78.0% (0.01) | 0.43% (0.06) | 86.9% (0.006) | |
| Uric acid | -0.74% (0.008) | -52.5% (0.005) | -0.92% (0.004) | -59.6% (0.004) | -0.51% (0.03) | -41.9% (0.01) | -0.50% (0.03) | -43.3% (0.006) | |
| Triglycerides | Calcium oxalate | 0.007% (0.88) | 0.95% (0.94) | 0.007% (0.89) | 0.56% (0.97) | 0.01% (0.81) | -2.3% (0.86) | 0.04% (0.45) | 1.5% (0.93) |
| Calcium phosphate | -0.19% (0.11) | -29.2% (0.11) | -0.19% (0.12) | -28.0% (0.13) | -0.18% (0.08) | -27.9% (0.11) | -0.12% (0.30) | -27.9% (0.14) | |
| Uric acid | 0.17% (0.16) | 48.4% (0.12) | 0.18% (0.13) | 53.1% (0.10) | 0.18% (0.10) | 37.4% (0.13) | 0.15% (0.22) | 40.7% (0.16) | |
| High-density lipoprotein | Calcium oxalate | -0.18% (0.66) | -6.7% (0.61) | -0.18% (0.66) | -6.8% (0.62) | 0.24% (0.53) | 10.1% (0.46) | 0.36% (0.39) | 8.5% (0.57) |
| Calcium phosphate | 0.92% (0.07) | 32.4% (0.17) | 0.91% (0.07) | 30.4% (0.19) | 1.2% (0.03) | 44.9% (0.10) | 0.81% (0.18) | 13.2% (0.62) | |
| Uric acid | -2.0% (0.001) | -48.3% (0.004) | -2.0% (0.001) | -48.8% (0.004) | -0.83% (0.14) | -17.3% (0.36) | -0.36% (0.55) | 1.3% (0.96) |
β: Slope expressed as percent change; p = p-value; Q4 vs. Q1: Lipid quartile contrast
Funding
- Private Foundation Support